U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Human Drug Compounding
  5. Inter-governmental Working Meeting on Pharmacy Compounding, September 20-21, 2016
  1. Human Drug Compounding

Inter-governmental Working Meeting on Pharmacy Compounding, September 20-21, 2016

Sign up for email alerts on Compounding

On September 20-21, 2016, FDA convened its fifth inter-governmental working meeting of state government officials, including the District of Columbia and Puerto Rico. Attendees included officials from state Boards of Pharmacy and State Health Departments, representatives from the National Association of Boards of Pharmacy (NABP) and the Federation of State Medical Boards (FSMB), and representatives from the Centers for Disease Control and Prevention (CDC).
 
The purpose of this meeting was to discuss oversight of compounding, including implementation of the Compounding Quality Act (CQA) (Title 1 of the Drug Quality and Security Act (DQSA)), and to identify opportunities to better protect the public health by strengthening oversight of compounders through improved federal-state collaboration.
 
FDA previously held inter-governmental working meetings on compounding with state officials and their designated representatives in December 2012, March 2014, March 2015, and November 2015. FDA initiated these meetings after the 2012 fungal meningitis outbreak associated with contaminated compounded drugs, which lead to many serious illnesses across the country.

Meeting Presentations